MBCproject_0280_T2_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0095142 | — | — | 0.845 |
| 2 | ERR2208899 | — | — | 0.845 |
| 3 | MBCProject_1819_T2B_RNA | — | D | 0.810 |
| 4 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.806 |
| 5 | SRR12202414 | — | — | 0.794 |
| 6 | SAMN03290914 | — | — | 0.791 |
| 7 | ERR4976622 | — | D | 0.785 |
| 8 | MBCProject_1509_T1_RNA | — | B | 0.775 |
| 9 | SRR8943017 | — | — | 0.773 |
| 10 | SRR8518313 | — | D | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |